A una de cada cuatro personas que decida aventurarse por la senda de la dieta cetogénica, le tocará enfrentarse a su «hiperrespuesta LDL» cuando se encuentre con un aumento notable del colesterol LDL (el comúnmente apodado «malo»), que además no vendrá solo, sino con una firme invitación a abandonar ipso facto esa nueva dieta y de medicarse para reducirlo… con estatinas.
Contenido adicional restringido. Para acceder a él, elige tu recorrido y adquiere tu dorsal.
¡Aúpa keto!
¿Quieres oír los episodios antes que nadie? Suscríbete al podcast en ivoox o escúchalos en Amazon Music, Apple Podcasts, Spotify Podcasts y SoundCloud.
¿Quieres, además, oírlo sin anuncios y descargarte la transcripción referenciada? ¡Consigue tu dorsal o tu pase VIP para la maratón y regodéate en las ketofilias VIP’s!
Referencias (por orden de aparición)
Aronica, L., Volek, J., Poff, A., & D’agostino, D. P. (2020). Genetic variants for personalised management of very low carbohydrate ketogenic diets. BMJ Nutrition, Prevention & Health, 3(2). https://doi.org/10.1136/bmjnph-2020-000167
Frantz, I. D., Jr, Dawson, E. A., Ashman, P. L., Gatewood, L. C., Bartsch, G. E., Kuba, K., & Brewer, E. R. (1989). Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. Arteriosclerosis, 9(1), 129–135. https://doi.org/10.1161/01.atv.9.1.129
Brown, M. S., & Goldstein, J. L. (1984). How LDL Receptors Influence Cholesterol and Atherosclerosis. Scientific American, 251(5), 58-69.
Brown, M. S., & Goldstein, J. L. (1996). Heart attacks: Gone with the Century? Science,272: 629.
Newman, J. (2013). Multiple Risk Factor Intervention Trial (MRFIT). En M. D. Gellman & J. R. Turner (Eds.), Encyclopedia of Behavioral Medicine (pp. 1273-1274). Springer. https://doi.org/10.1007/978-1-4419-1005-9_1277
Stamler, J., Wentworth, D., & Neaton, J. D. (1986). Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA, 256(20), 2823-2828.
Goldstein, J. L., & Brown, M. S. (2015). A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. Cell, 161(1), 161-172. https://doi.org/10.1016/j.cell.2015.01.036
Ramsden, C. E., …, Frantz, R. P., … & Hibbeln, J. R. (2016). Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ (Clinical research ed.), 353, i1246. https://doi.org/10.1136/bmj.i1246
Begley, S. (2017). Records Found in Dusty Basement Undermine Decades of Dietary Advice. Scientific American. https://www.scientificamerican.com/article/records-found-in-dusty-basement-undermine-decades-of-dietary-advice/
Lite, J. (2008). Scientific American. Cholesterol drug scientist receives «America’s Nobel»: Endo pinpointed basis for statins. https://blogs.scientificamerican.com/news-blog/cholesterol-drug-scientist-receives-2008-09-12/
Diamond, D. M., & Ravnskov, U. (2015). How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. Expert Review of Clinical Pharmacology, 8(2), 201-210. https://doi.org/10.1586/17512433.2015.1012494
Abramson, J. D., & Redberg, R. F. (2013). Don’t Give More Patients Statins. The New York Times. https://www.nytimes.com/2013/11/14/opinion/dont-give-more-patients-statins.html
Mansi, I. A., … & Alvarez, C. A. (2021). Association of Statin Therapy Initiation With Diabetes Progression. JAMA Internal Medicine, 181(12), 1562-1574. https://doi.org/10.1001/jamainternmed.2021.5714
Bruckert, E., Giral, P., Heshmati, H. M., & Turpin, G. (1996). Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. Journal of Clinical Pharmacy and Therapeutics, 21(2), 89-94. https://doi.org/10.1111/j.1365-2710.1996.tb00006.x
Acharya, T., … & Mansi, I. A. (2016). Statin Use and the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study). The American Journal of Cardiology, 117(4), 647-655. https://doi.org/10.1016/j.amjcard.2015.11.031
Leutner, M., … & Kautzky-Willer, A. (2019). Diagnosis of osteoporosis in statin-treated patients is dose-dependent. Annals of the Rheumatic Diseases, 78(12), 1706-1711. https://doi.org/10.1136/annrheumdis-2019-215714
Mansi, I., … & Mortensen, E. M. (2013). Statins and Musculoskeletal Conditions, Arthropathies, and Injuries. JAMA Internal Medicine, 173(14), 1318-1326. https://doi.org/10.1001/jamainternmed.2013.6184
Liu, G., Sterling, N. W., Kong, L., Lewis, M. M., Mailman, R. B., Chen, H., Leslie, D., & Huang, X. (2017). Statins may facilitate Parkinson’s disease: Insight gained from a large, national claims database. Movement Disorders, 32(6), 913-917. https://doi.org/10.1002/mds.27006
Padala, K. P., … & Potter, J. F. (2012). The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: A prospective withdrawal and rechallenge pilot study. The American Journal of Geriatric Pharmacotherapy, 10(5), 296-302. https://doi.org/10.1016/j.amjopharm.2012.08.002
Morris, Z. S., Wooding, S., & Grant, J. (2011). The answer is 17 years, what is the question: Understanding time lags in translational research. Journal of the Royal Society of Medicine, 104(12), 510-520. https://doi.org/10.1258/jrsm.2011.110180
Kendrick, M. (2007). Great Cholesterol Con: The Truth About What Really Causes Heart Disease and How to Avoid It. Disponible en Amazon.
Harcombe, Z. (2010). The Obesity Epidemic: What caused it? How can we stop it? Disponible en Amazon.
Marotta, T., Russo, B. F., & Ferrara, L. A. (2010). Triglyceride-to-HDL-cholesterol ratio and metabolic syndrome as contributors to cardiovascular risk in overweight patients. Obesity (Silver Spring, Md.), 18(8), 1608–1613. https://doi.org/10.1038/oby.2009.446
